FB23-2

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

FB23-2 can also prevent osteogenic differentiation of human mesenchymal stem cells (MSCs). It is capable of delaying leukemogenesis in vivo. In mice, FB23-2 at a dose of 20 mg/kg is safe for testing in vivo efficacy.

FB23-2 is a cell penetrant, potent and specific inhibitor of N6-methyladenosine (m6A) demethylase FTO (fat mass and obesity associated protein) that RNA methylation in varies of AML cells. FB23-2 potently inhibits proliferation and promotes apoptosis and differentiation in human acute myeloid leukemia (AML) cells and primary blast AML cells lines and xenografts in mice. It minimally affects proliferation of human normal bone marrow cells.